Literature DB >> 18634869

Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis.

Vincenzina Lucidi1, Giovanni Ciabattoni, Sergio Bella, Peter J Barnes, Paolo Montuschi.   

Abstract

We measured 8-isoprostane, a biomarker of oxidative stress, and prostaglandin (PG) E(2) in exhaled breath condensate in 36 stable and 14 unstable cystic fibrosis (CF) patients, and in 15 healthy age-matched controls. We studied the relationships of these eicosanoids with clinical, radiological, and systemic inflammatory parameters. Compared with controls [15.5 (11.5-17.0) pg/ml] exhaled 8-isoprostane was increased in stable CF patients [30.5 (25.3-36.0) pg/ml, P<0.001]. Unstable CF patients had higher exhaled 8-isoprostane levels [47.5 (44.0-50.0) pg/ml, P<0.001] than stable CF patients. Unlike PGE(2), exhaled 8-isoprostane was negatively correlated with FEV(1) (r=-0.67; P<0.0001; r=-0.63; P<0.02) and Shwachman score (r=-0.43, P=0.012; r=-0.58, P=0.031) and positively correlated with Chrispin-Norman score (r=0.51, P<0.002; r=0.56, P=0.039) in stable and unstable CF patients, respectively. No correlation was observed with C-reactive protein. Compared with controls [41.0 (29.0-50.0) pg/ml], exhaled PGE(2) was also elevated in stable [72.0 (64.3-81.8) pg/ml, P<0.001) and, to a greater extent, in unstable CF patients [83.0 (74.3-91.3) pg/ml, P<0.001). In patients with CF, exhaled 8-isoprostane and PGE(2) could be a useful marker of disease severity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634869     DOI: 10.1016/j.freeradbiomed.2008.06.026

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  25 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

Review 2.  Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.

Authors:  C N Belcher; N Vij
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

3.  The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.

Authors:  Michael Glenn O'Connor; Adam Seegmiller
Journal:  J Cyst Fibros       Date:  2016-07-26       Impact factor: 5.482

4.  Hemoglobin attenuates the effects of inspired oxygen on plasma isofurans in humans during upper-limb surgery.

Authors:  Tomas B Corcoran; Anne E Barden; Emilie Mas; Sina Grape; Viktoria Koren; Michael Phillips; L Jackson Roberts; Trevor A Mori
Journal:  Free Radic Biol Med       Date:  2011-06-27       Impact factor: 7.376

5.  Exhaled breath condensate pH in patients with cystic fibrosis.

Authors:  Balazs Antus; Imre Barta; Eszter Csiszer; Krisztina Kelemen
Journal:  Inflamm Res       Date:  2012-06-16       Impact factor: 4.575

6.  Respiratory syncytial virus infection down-regulates antioxidant enzyme expression by triggering deacetylation-proteasomal degradation of Nrf2.

Authors:  Narayana Komaravelli; Bing Tian; Teodora Ivanciuc; Nicholas Mautemps; Allan R Brasier; Roberto P Garofalo; Antonella Casola
Journal:  Free Radic Biol Med       Date:  2015-06-11       Impact factor: 7.376

7.  Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice.

Authors:  Gregory S Harmon; Darren S Dumlao; Damian T Ng; Kim E Barrett; Edward A Dennis; Hui Dong; Christopher K Glass
Journal:  Nat Med       Date:  2010-02-14       Impact factor: 53.440

8.  The thioredoxin reductase-1 inhibitor aurothioglucose attenuates lung injury and improves survival in a murine model of acute respiratory distress syndrome.

Authors:  Rodney D Britt; Markus Velten; Morgan L Locy; Lynette K Rogers; Trent E Tipple
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

Review 9.  Developmental regulation of antioxidant enzymes and their impact on neonatal lung disease.

Authors:  Sara K Berkelhamer; Kathryn N Farrow
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

Review 10.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.